Vibrant Therapeutics Raises $61M and Appoints Han Lee, Ph.D. as Co-CEO
Vibrant Therapeutics (“Vibrant”), a clinical-stage biotechnology company developing next-generation intelligent therapeutics, today announced $61 million in new financing. The financing includes new investors Pfizer Ventures and Apricot Capital with participation from Bayland Capital, HSG, Northern Light Venture Capital, and First Principle Venture Limited. This brings Vibrant’s total capital raised to $100 million.
